Pharma Solid Form Analysis – Advance your analysis with XRD

Log in to watch this webinar

Not registered yet? Create an account
00:00:00 Why solid form analysis
00:05:13 Quality by Design
00:08:16 What can be considered CMA
00:11:12 Solutions for solid form analysis
00:14:31 Crystallization monitoring
00:15:52 Online monitoring benefits
00:16:22 In-situ studies
00:20:09 Polymorph case study
00:29:38 Summary
00:31:22 Q & A

Setting meaningful and realistic specifications for pharmaceutical product Critical Material Attributes (CMAs) is an important in ensuring a product meets its target performance profile. Within this, the polymorphism and crystallinity of the Active Pharmaceutical Ingredients (APIs) and excipients present within a product formulation are crucial. Presence of an undesired polymorph could lead to a reduction in therapeutic benefit, due to changes in API solubility, and may even cause an adverse effect to the patient. Polymorph selection, and conformation of polymorphic stability over time, is therefore vital. This becomes even more important when an amorphous form of the API is selected to improve solubility, as unexpected crystallization of an insoluble form can be fatal.

This webinar series will consider the guidance available regarding polymorph and crystallinity analysis for pharmaceutical products and how appropriate methods can be developed using the technique of X-Ray Powder Diffraction (XRPD).

In this first presentation we will discuss why a polymorph specification may be required. We’ll review the guidance provided in ICH Q6A, which recommends that formulation developers consider how product bioavailability, uniformity, stability and processability may be impacted by structural changes. We will then consider how XRPD can aid formulation developers in material selection and in understanding the impact of formulation processing operations on product performance.

Join our series of Pharma oral solid dose drugs analysis

- Webinar 1: Polymorphic and crystallinity screening of your APIs and more in your oral solid dose drugs using X-ray diffraction
- Webinar 2: Advanced polymorphic screening using in-situ measurements. More info 
- Webinar 3: Introduction to powder X-ray diffraction. More info
- Webinar 4: Checking the stability, efficacy and performance of your APIs with particle size analysis using laser diffraction. More info


Dr Natalia Dadivanyan, XRD Application Specialist, Malvern Panalytical's Supply Center in the Netherlands
Dr Natalia studied chemistry at Moscow State University (Russia). After completing her master thesis on synthesis and characterization of polymer liquid crystalline films Natalia moved to University of Freiburg (Germany) to obtain her PhD degree working on liquid crystalline elastomers. This was followed by a post-doc position at the Eindhoven University of Technology (The Netherlands), where Natalia focused on organic semi-conductors. In 2012 Natalia joined Malvern Panalytical as an Application Specialist XRD, in Almelo (The Netherlands).

Dr Sandeep Nagar, XRD Application Specialist at Malvern Panalytical
Dr Nagar has 16 years of R and D experience. He completed his PhD in Materials Science from KTH Sweden in 2012. He thereafter taught at various Indian universities as an Assistant Professor for 6 years. In 2018, he joined Malvern Panalytical as an application specialist for X-ray diffraction. In his work, he has provided application and technical support to customers from various industries including academic research, to mining, steel, cement, pharmaceuticals and more. His area of specialty is in mineralogical and structural research using X-ray diffraction.


Join our series of Pharma oral solid dose drugs analysis using XRD
- Webinar 1: Advanced your analysis with X-ray diffraction
- Webinar 2: Expanding your analysis using XRD. More info
- Webinar 3: Introduction to powder XRD. More info